Why the study?
While first-line anthracyclines remain the standard of care for advanced sts, the choice of subsequent therapy beyond anthracyclines remains challenging.
Anthracyclines remain the standard first-line therapy for advanced soft-tissue sarcoma, with ongoing developments in novel therapies and molecular diagnostics for subsequent lines of treatment.
Anthracyclines remain first-line for advanced soft-tissue sarcoma; leaves open optimal sequencing of novel agents in later lines.
First-line systemic therapy with an anthracycline remains the standard of care for advanced sts. However, choice of subsequent therapy beyond anthracyclines remains challenging. Novel systemic therapies, use of molecular diagnostics to direct therapy, subtype-specific trials, and learnings from real-world retrospective data are all important for improving outcomes in patients with advanced sts.
No takes yet. Share an insight, caveat, or question.
Smrke et al. (2020) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: